Everything below concerns metabolite. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Glycerol () is a sugar alcohol with chemical formula C3H5(OH)3. It has three carbon atoms with one hydroxyl group on each. Glycerol is a colorless, odorless, sweet-tasting, viscous liquid at Standard Ambient Temperature and Pressure (SATP). Because of its three hydroxyl groups, glycerol is miscible with water and is hygroscopic in nature. The glycerol backbone is found in lipids known as glycerides, where one or more of the hydroxyl groups are esterified with fatty acids. The most abundant of glycerides are triglycerides (found in animal fats and vegetable oils), the form in which glycerol is most commonly found in nature. It is also widely used as a sweetener in the food industry and as a humectant in pharmaceutical formulations. Modern use of the word glycerine (alternatively spelled glycerin) refers to commercial preparations of glycerol that are less than 100% pure, typically 95%.
=== Thirlwall inquiry === After Letby's conviction, the British government announced an independent inquiry into "the circumstances surrounding the deaths and incidents, including how concerns raised by clinicians were dealt with". It was initially established on a non‑statutory basis, meaning witnesses could not be compelled to give evidence and inquests would still be required. Senior figures at the Countess of Chester Hospital, including the medical director, chief executive and nursing director at the time of the incidents, said they would cooperate. The medical director retired in August 2018, and the chief executive resigned the following month after signing a non‑disclosure agreement. Families represented by the law firm Slater and Gordon called for the inquiry to be given statutory powers, arguing that a non‑statutory process relied on the goodwill of witnesses. Similar calls were made by former Justice Secretary Sir Robert Buckland, Chester MP Samantha Dixon, Steve Brine, chair of the Health and Social Care Select Committee, Sir Keir Starmer, then Leader of the Opposition, and the Parliamentary and Health Service Ombudsman. In August 2024, a group of 24 neonatal and statistical experts wrote to ministers requesting that the inquiry be postponed and its terms amended, citing concerns about the safety of Letby's convictions. The inquiry declined to make changes. Education Secretary Gillian Keegan said the type of inquiry would be reviewed once a chair was appointed.
== Season 3 (2017) == Eight bakers competed in a six-episode baking tournament. One person got eliminated every week until the final three compete for $25,000. Judges for this season are Carla Hall, Zac Young, and Lorraine Pascale.
==== LL Cool J ==== Ice-T had a feud with LL Cool J in the late 1980s and early 1990s. Apparently, this was instigated by LL's claim to be "the baddest rapper in the history of rap itself". Ice-T recorded disses against LL on his 1988 album Power. On the album was the track, "I'm Your Pusher", in which a rap music addict declines to buy an LL Cool J record. In the book Check the Technique: Liner Notes for Hip-Hop Junkies, Ice-T said that the song "Girls L.G.B.N.A.F." was also intended as a diss to LL Cool J, by making a crude song to contrast with the love songs that LL was making at the time. On LL's response, "To da Break of Dawn" in 1990, he dissed Kool Moe Dee (whose feud with LL was far more publicized) as well as MC Hammer. He then devoted the third verse of the song to dissing Ice-T, mocking his rap ability ("take your rhymes around the corner to rap rehab"), his background ("before you rapped, you was a downtown car thief"), and his style ("a brother with a perm deserves to get burned"). He also suggested that the success of Power was due to the appearance of Ice-T's girlfriend Darlene on the album cover. Ice-T appeared to have ignored the insults and he had also defended LL Cool J after his arrest in the song "Freedom of Speech". In August 2012, Ice-T said that the rivalry was "never serious" and that he needed a nemesis to create "an exciting dispute".
== Clinical significance == The multiple roles of moonlighting proteins complicates the determination of phenotype from genotype, hampering the study of inherited metabolic disorders. The complex phenotypes of several disorders are suspected to be caused by the involvement of moonlighting proteins. The protein GAPDH has at least 11 documented functions, one of which includes apoptosis. Excessive apoptosis is involved in many neurodegenerative diseases, such as Huntington's, Alzheimer's, and Parkinson's as well as in brain ischemia. In one case, GAPDH was found in the degenerated neurons of individuals who had Alzheimer's disease. Although there is insufficient evidence for definite conclusions, there are well documented examples of moonlighting proteins that play a role in disease. One such disease is tuberculosis. One moonlighting protein in M. tuberculosis has a function which counteracts the effects of antibiotics. Specifically, the bacterium gains antibiotic resistance against ciprofloxacin from overexpression of glutamate racemase in vivo. GAPDH localized to the surface of pathogenic mycobacteria has been shown to capture and traffic the mammalian iron carrier protein transferrin into cells resulting in iron acquisition by the pathogen.
Sources: en.wikipedia.org
coordination complex A chemical compound consisting of a central atom or ion, usually metallic and known as the coordination center, bonded to a surrounding array of other groups of atoms, e.g. molecules or ions, which are known as ligands or complexing agents. Many metal-containing compounds, especially those of the transition metals, are coordination complexes. See also complex.
=== King's Police Medal (KPM) === Bernard Kenneth Bonamy Jr., Assistant Commissioner of Police, Royal Bahamas Police Force. Theophilus Andrew Cunningham. Assistant Commissioner of Police, Royal Bahamas Police Force.
==== Yeast Two-hybrid Screens ==== Yeast two-hybrid analyses have been adapted for protease-substrate discovery. As protease exosites play roles in protein-protein recognition and interaction, biologists have used exosites as tools to screen for protease interactors and potential substrates. These protease exosite scanning assays use protease exosites as bait to scan a cDNA library for possible interacting partners. Another early adaptation of yeast two-hybrid screening in protease-substrate discovery is Inactive-catalytic-domain capture (ICDC). This approach attempts to avoid the limitation of protease exosite scanning, which fails to account for any substrates that do not require exosites to for recognition before cleavage. The bait for these assays are immobilized catalytically inactive mutant protease domains that cannot cleave and release their substrates once bound. While useful in early degradomic studies, the limitations of adapted yeast two-hybrid screens have forced the field to move on to higher-throughput approaches for protease-substrate discovery. Their high rate of false positives and negatives, inability to recognize complex interactions, lack of biologically compartmentalization, and failure to account for post-translational modifications necessary for protein-protein interactions hamper their usefulness. Thus they have been largely replaced by proteomic methods as technology has improved.
is the fraction of all possible contacts that involves an infectious and susceptible individual. (This is mathematically similar to the law of mass action in chemistry in which random collisions between molecules result in a chemical reaction and the fractional rate is proportional to the concentration of the two reactants.) Between I and R, the transition rate is assumed to be proportional to the number of infectious individuals which is
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.